{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T03:13:22Z","timestamp":1792206802528,"version":"4.4.0"},"reference-count":45,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T00:00:00Z","timestamp":1752192000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Periodic vaccination against COVID-19 persists with a recommendation to vaccinate especially older people and the chronically ill. However, vaccination compliance is low, likely due to concerns regarding adverse events (AEs).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective<\/jats:title>\n<jats:p>To systematically and proactively evaluate the occurrence, onset, duration, and severity of self-reported AEs and comorbidities exacerbations that appeared up to 21\u201330 days following the third (booster) Pfizer BNT162b2 vaccine dose, and to examine the associations between the occurrence of any AEs and sociodemographic and pre-existing comorbidities.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>A cross-sectional telephone survey among a nationally representative sample of Israeli vaccinated adults aged \u226518 was conducted from September through October 2021. Sociodemographic data was extracted from the Ministry of Health vaccination database, and data on AEs and comorbidities were collected using a structured questionnaire.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Overall, 2,049 participants completed the survey (71.4% response rate). A total of 1360 (66.4%) reported at least one AE following the booster vaccine. The most frequently reported AEs were local (55.7%) and mild systemic (48.6%) reactions (i.e., fatigue, headache, fever), followed by neurological (4.5%) and allergic (3.9%) reactions. Exacerbation of comorbidities following the booster dose was most frequently reported by individuals with autoimmune or mental conditions. Most local (80.1%) and systemic (69.5%) reactions lasted up to three days. Only 8.3% sought medical care. Menstrual changes were reported by 9.6% of women aged &lt;54 years. The occurrence of any AEs was associated with younger age, female gender, higher socioeconomic status, and living in suburban communities. AEs were not associated with pre-existing comorbidities.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Most AEs were mild to moderate and transient. They were associated with younger age, but not with pre-existing chronic diseases. Since the primary target population for vaccination consists of older individuals and those with comorbidities, we believe the current findings may assist in reducing COVID-19 vaccine hesitancy among these populations.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0326231","type":"journal-article","created":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T17:45:56Z","timestamp":1752255956000},"page":"e0326231","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Evaluation of adverse events and comorbidity exacerbation following the COVID-19 booster dose: A national survey among randomly-selected booster recipients"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3266-6491","authenticated-orcid":true,"given":"Dvora","family":"Frankenthal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8289-9923","authenticated-orcid":true,"given":"Miri","family":"Zatlawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziv","family":"Karni-Efrati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lital","family":"Keinan-Boker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aharona","family":"Glatman-Freedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Bromberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,7,11]]},"reference":[{"key":"pone.0326231.ref001","doi-asserted-by":"crossref","first-page":"103574","DOI":"10.1016\/j.ebiom.2021.103574","article-title":"The BNT162b2 vaccine effectiveness against new COVID-19 cases and complications of breakthrough cases: a nation-wide retrospective longitudinal multiple cohort analysis using individualised data","volume":"72","author":"A Glatman-Freedman","year":"2021","journal-title":"EBioMedicine"},{"issue":"3","key":"pone.0326231.ref002","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciac524","article-title":"Vaccine coverage associated with ending a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) wave: a retrospective longitudinal analysis","volume":"76","author":"A Glatman-Freedman","year":"2023","journal-title":"Clin Infect Dis"},{"key":"pone.0326231.ref003","author":"Centers for Disease Control and Prevention","year":"2024"},{"key":"pone.0326231.ref004","volume-title":"CDC Recommends Second Dose of 2024-2025 COVID-19 Vaccine for People 65 Years and Older and for People Who Are Moderately or Severely Immunocompromised","author":"Centers for Disease Control and Prevention","year":"2024"},{"key":"pone.0326231.ref005","doi-asserted-by":"crossref","first-page":"1054557","DOI":"10.3389\/fmed.2022.1054557","article-title":"COVID-19 vaccine and booster hesitation around the world: a literature review","volume":"9","author":"A Shah","year":"2023","journal-title":"Front Med (Lausanne)"},{"issue":"2","key":"pone.0326231.ref006","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3390\/vaccines11020369","article-title":"Demographic differences in compliance with COVID-19 vaccination timing and completion guidelines in the United States","volume":"11","author":"P Zhu","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"pone.0326231.ref007","author":"Medicines & Healthcare products Regulatory Agency","year":"2023"},{"key":"pone.0326231.ref008","author":"Centers for Disease Control and Prevention"},{"key":"pone.0326231.ref009","author":"Israel Ministry of Health"},{"key":"pone.0326231.ref010","author":"Australian Government Department of Health and Aged Care"},{"key":"pone.0326231.ref011","author":"Paul-Ehrlich-Institute"},{"issue":"6","key":"pone.0326231.ref012","doi-asserted-by":"crossref","first-page":"396","DOI":"10.24171\/j.phrp.2021.0310","article-title":"COVID-19 vaccine safety monitoring in Republic of Korea from February 26, 2021 to October 31, 2021","volume":"12","author":"I Hwang","year":"2021","journal-title":"Osong Public Health Res Perspect"},{"key":"pone.0326231.ref013","first-page":"100442","article-title":"Safety monitoring of COVID-19 vaccines in Japan","volume":"23","author":"T Yamaguchi","year":"2022","journal-title":"Lancet Reg Health West Pac"},{"issue":"2","key":"pone.0326231.ref014","article-title":"Incidence and nature of short-term adverse events following COVID-19 second boosters: insights from Taiwan\u2019s universal vaccination strategy","volume":"12","author":"CH Lin","year":"2024","journal-title":"Vaccines"},{"issue":"47","key":"pone.0326231.ref015","doi-asserted-by":"crossref","first-page":"7458","DOI":"10.1016\/j.vaccine.2020.09.072","article-title":"The reporting sensitivity of the Vaccine Adverse Event Reporting System (VAERS) for anaphylaxis and for Guillain-Barr\u00e9 syndrome","volume":"38","author":"ER Miller","year":"2020","journal-title":"Vaccine"},{"key":"pone.0326231.ref016","author":"Centers for Disease Control and Prevention"},{"key":"pone.0326231.ref017","doi-asserted-by":"crossref","first-page":"112022","DOI":"10.1016\/j.intimp.2024.112022","article-title":"Comparative safety profile of bivalent and original COVID-19 mRNA vaccines regarding myocarditis\/pericarditis: a pharmacovigilance study","volume":"133","author":"C Chen","year":"2024","journal-title":"Int Immunopharmacol"},{"issue":"4","key":"pone.0326231.ref018","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1007\/s00277-023-05136-2","article-title":"Analysis of hematologic adverse events reported to a national surveillance system following COVID-19 bivalent booster vaccination","volume":"102","author":"JW Jacobs","year":"2023","journal-title":"Ann Hematol"},{"issue":"30","key":"pone.0326231.ref019","doi-asserted-by":"crossref","first-page":"971","DOI":"10.15585\/mmwr.mm7130a4","article-title":"Safety monitoring of COVID-19 mRNA vaccine second booster doses among adults aged \u226550 years - United States, March 29, 2022-July 10, 2022","volume":"71","author":"AM Hause","year":"2022","journal-title":"MMWR Morbidity Mortality Weekly Report"},{"issue":"32","key":"pone.0326231.ref020","doi-asserted-by":"crossref","first-page":"4666","DOI":"10.1016\/j.vaccine.2023.06.014","article-title":"Evaluation of potential adverse events following COVID-19 mRNA vaccination among adults aged 65 years and older: Two self-controlled studies in the U.S","volume":"41","author":"A Shoaibi","year":"2023","journal-title":"Vaccine"},{"issue":"10","key":"pone.0326231.ref021","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/S1473-3099(23)00207-4","article-title":"Safety of monovalent and bivalent BNT162b2 mRNA COVID-19 vaccine boosters in at-risk populations in Israel: a large-scale, retrospective, self-controlled case series study","volume":"23","author":"D Yamin","year":"2023","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"pone.0326231.ref022","doi-asserted-by":"crossref","first-page":"6085","DOI":"10.1038\/s41467-024-49634-x","article-title":"Cohort study of cardiovascular safety of different COVID-19 vaccination doses among 46 million adults in England","volume":"15","author":"S Ip","year":"2024","journal-title":"Nat Commun"},{"issue":"4","key":"pone.0326231.ref023","doi-asserted-by":"crossref","first-page":"771","DOI":"10.3201\/eid2904.221285","article-title":"Effectiveness of BNT162b2 vaccine against omicron variant infection among children 5-11 years of age, Israel","volume":"29","author":"A Glatman-Freedman","year":"2023","journal-title":"Emerging Infectious Dis"},{"issue":"7","key":"pone.0326231.ref024","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S1473-3099(21)00224-3","article-title":"Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study","volume":"21","author":"C Menni","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"7","key":"pone.0326231.ref025","article-title":"Risk factors and incidence rates of self-reported short-term adverse events of COVID-19 vaccine booster dose","volume":"10","author":"PY Chen","year":"2022","journal-title":"Vaccines"},{"key":"pone.0326231.ref026","article-title":"Adverse events of COVID-19 vaccines in the United States: temporal and spatial analysis","volume":"10","author":"Y Li","year":"2024","journal-title":"JMIR Public Health Surveill"},{"issue":"44","key":"pone.0326231.ref027","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.15585\/mmwr.mm7144a3","article-title":"Safety monitoring of bivalent COVID-19 mRNA vaccine booster doses among persons aged \u226512 Years - United States, August 31-October 23, 2022","volume":"71","author":"AM Hause","year":"2022","journal-title":"MMWR Morbidity Mortality Weekly Rep"},{"issue":"2","key":"pone.0326231.ref028","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s40264-021-01138-z","article-title":"Spontaneous reporting to regulatory authorities of suspected adverse drug reactions to COVID-19 vaccines over time: the effect of publicity","volume":"45","author":"RE Ferner","year":"2022","journal-title":"Drug Saf"},{"key":"pone.0326231.ref029","author":"World Health Organization","year":"2024"},{"issue":"9","key":"pone.0326231.ref030","doi-asserted-by":"crossref","first-page":"977","DOI":"10.3390\/vaccines9090977","article-title":"Occurrence of BNT162b2 vaccine adverse reactions is associated with enhanced SARS-CoV-2 IgG antibody response","volume":"9","author":"Y Rechavi","year":"2021","journal-title":"Vaccines (Basel)"},{"issue":"5","key":"pone.0326231.ref031","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S1473-3099(10)70049-9","article-title":"The Xs and Y of immune responses to viral vaccines","volume":"10","author":"SL Klein","year":"2010","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"pone.0326231.ref032","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s00281-018-0726-5","article-title":"Sex differences in vaccine-induced humoral immunity","volume":"41","author":"S Fischinger","year":"2019","journal-title":"Semin Immunopathol"},{"key":"pone.0326231.ref033","doi-asserted-by":"crossref","first-page":"581426","DOI":"10.3389\/fpsyt.2020.581426","article-title":"Worsening of preexisting psychiatric conditions during the COVID-19 pandemic","volume":"11","author":"S Gobbi","year":"2020","journal-title":"Front Psychiatry"},{"key":"pone.0326231.ref034","first-page":"13","article-title":"Impact of COVID-19 pandemic on patients with Serious Mental Illness (SMI) and nonpsychiatric control subjects in clinical trials","volume":"21","author":"M Fe Garcia-Rada","year":"2024","journal-title":"Innov Clin Neurosci"},{"issue":"11","key":"pone.0326231.ref035","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1001\/jamapsychiatry.2024.2339","article-title":"COVID-19 and mental illnesses in vaccinated and unvaccinated people","volume":"81","author":"VM Walker","year":"2024","journal-title":"JAMA Psychiatry"},{"issue":"12","key":"pone.0326231.ref036","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1093\/rheumatology\/kead144","article-title":"Flares in autoimmune rheumatic diseases in the post-COVID-19 vaccination period-a cross-sequential study based on COVAD surveys","volume":"62","author":"K Jagtap","year":"2023","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"pone.0326231.ref037","doi-asserted-by":"crossref","DOI":"10.1111\/1756-185X.70001","article-title":"COVID-19 vaccination in patients with systemic lupus erythematosus: adverse events and rating agreement of flares between patients and physicians","volume":"27","author":"P Tangkum","year":"2024","journal-title":"Int J Rheum Dis"},{"issue":"2","key":"pone.0326231.ref038","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/AOG.0000000000005476","article-title":"Prolongation of the menstrual cycle after receipt of the primary series and booster doses of mRNA coronavirus disease 2019 (COVID-19) vaccination","volume":"143","author":"S Hosoya","year":"2024","journal-title":"Obstetrics Gynecol"},{"issue":"1","key":"pone.0326231.ref039","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/AOG.0000000000005343","article-title":"Associations among menstrual cycle length, coronavirus disease 2019 (COVID-19), and vaccination","volume":"143","author":"A Alvergne","year":"2024","journal-title":"Obstetrics Gynecol"},{"issue":"2","key":"pone.0326231.ref040","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s43032-022-01062-2","article-title":"Abnormal uterine bleeding among COVID-19 vaccinated and recovered women: a national survey","volume":"30","author":"G Issakov","year":"2023","journal-title":"Reprod Sci"},{"key":"pone.0326231.ref041","doi-asserted-by":"crossref","first-page":"100419","DOI":"10.1016\/j.jvacx.2023.100419","article-title":"Nationwide safety surveillance of COVID-19 mRNA vaccines following primary series and first booster vaccination in Singapore","volume":"15","author":"SR Dorajoo","year":"2023","journal-title":"Vaccine X"},{"issue":"15","key":"pone.0326231.ref042","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12154971","article-title":"Myocarditis and Pericarditis Post-mRNA COVID-19 vaccination: insights from a pharmacovigilance perspective","volume":"12","author":"A Alami","year":"2023","journal-title":"J Clin Med"},{"key":"pone.0326231.ref043","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ijid.2023.03.027","article-title":"A population-based assessment of myocarditis after messenger RNA COVID-19 booster vaccination among adult recipients","volume":"131","author":"Z Naveed","year":"2023","journal-title":"Int J Infect Dis"},{"issue":"23","key":"pone.0326231.ref044","doi-asserted-by":"crossref","first-page":"126026","DOI":"10.1016\/j.vaccine.2024.05.074","article-title":"Effectiveness against severe COVID-19 of a seasonal booster dose of bivalent (original\/Omicron BA.4-5) mRNA vaccines in persons aged \u226560 years: Estimates over calendar time and by time since administration during prevalent circulation of different Omicron subvariants, Italy, 2022-2023","volume":"42","author":"M Fabiani","year":"2024","journal-title":"Vaccine"},{"key":"pone.0326231.ref045","doi-asserted-by":"crossref","first-page":"100755","DOI":"10.1016\/j.lanepe.2023.100755","article-title":"Vaccine effectiveness against hospitalisation estimated using a test-negative case-control study design, and comparative odds of hospital admission and severe outcomes with COVID-19 sub-lineages BQ.1, CH.1.1. and XBB.1.5 in England","volume":"35","author":"FCM Kirsebom","year":"2023","journal-title":"Lancet Reg Health Eur"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0326231","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T17:46:03Z","timestamp":1752255963000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0326231"}},"subtitle":[],"editor":[{"given":"Amirhossein","family":"Akhavan-Sigari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,7,11]]},"references-count":45,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7,11]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0326231","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,11]]}}}